Cargando…

Induction Treatment in Transplant-eligible Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Quinn, J., Glavey, S., Comerford, C., Murphy, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078356/ https://www.ncbi.nlm.nih.gov/pubmed/33912811 http://dx.doi.org/10.1097/HS9.0000000000000560

Ejemplares similares

PB1996: TREATMENT PATHWAYS AT FIRST RELAPSE POST-ASCT IN MULTIPLE MYELOMA: IMPACT OF MAINTENANCE THERAPY ON TREATMENT OPTIONS
por: Duane, C., et al.
Publicado: (2022)

Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma
por: Comerford, Claire, et al.
Publicado: (2022)

The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies
por: Comerford, Claire, et al.
Publicado: (2022)

Comment on “Outcomes of autologous transplantation for multiple myeloma according to different induction regimens”
por: de la Rubia, Javier
Publicado: (2014)

Genetic Abnormalities in Extramedullary Multiple Myeloma
por: McAvera, Roisin, et al.
Publicado: (2023)

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
por: Swan, Dawn, et al.
Publicado: (2023)

Emergence of chronic myeloid leukemia following autologous stem cell transplantation in a young woman with multiple myeloma
por: Barrett, Aisling, et al.
Publicado: (2018)

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
por: Bobin, Arthur, et al.
Publicado: (2020)

Multiple Myeloma and the Kidney
por: Cancarini, Giovanni, et al.
Publicado: (2021)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

How I manage frontline transplant-eligible multiple myeloma in Italy
por: Montefusco, Vittorio, et al.
Publicado: (2020)

Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
por: Shackleton, Louisa, et al.
Publicado: (2020)

Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients
por: Barrett, Aisling, et al.
Publicado: (2021)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
por: Crusoe, E., et al.
Publicado: (2022)

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
por: Paquin, Ashley R., et al.
Publicado: (2018)

Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia
por: Qerimi, Vjollca, et al.
Publicado: (2018)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
por: Zamagni, Elena, et al.
Publicado: (2020)

Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials
por: Zeng, Zi-Hang, et al.
Publicado: (2017)

Management of patients with multiple myeloma during the COVID-19 pandemic
por: Malard, Florent, et al.
Publicado: (2020)

Impact of COVID-19 on preparation for the Certificate of Eligibility for Specialist Registration (CESR) in Ophthalmology
por: Al-Hayouti, Huda, et al.
Publicado: (2021)

PB1992: HISPANIC ETHNICITY AS A STRONG PREDICTOR OF POOR RESPONSE TO INDUCTION THERAPY AND ASCT IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Chineke, I., et al.
Publicado: (2022)

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
por: Chacon, Aurelia, et al.
Publicado: (2023)

Gene expression profiling as a prognostic tool in multiple myeloma
por: Black, Harmony, et al.
Publicado: (2021)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
por: Bird, Sarah, et al.
Publicado: (2021)

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Induction therapy and stem-cell mobilization in myeloma, look at the past to plan the future()
por: Schaffel, Rony
Publicado: (2019)

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
por: Wester, Ruth, et al.
Publicado: (2019)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
por: Blommestein, Hedwig M., et al.
Publicado: (2019)

Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation
por: Hu, Sai-Ling, et al.
Publicado: (2022)

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
por: Wester, Ruth, et al.
Publicado: (2020)

Should UK Pneumococcal Vaccine Eligibility Criteria Include Alcohol Dependency in Areas with High Alcohol-Related Mortality?
por: Mooney, John D., et al.
Publicado: (2018)

Multiple myeloma and infection: this association is still close
por: Garnica, Marcia
Publicado: (2019)

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients
por: Panopoulou, Aikaterini, et al.
Publicado: (2023)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Popková, Tereza, et al.
Publicado: (2023)

Visualizing the Heterogeneity of Effects in the Analysis of Associations of Multiple Myeloma with Glyphosate Use. Comments on Sorahan, T. Multiple Myeloma and Glyphosate Use: A Re-Analysis of US Agricultural Health Study (AHS) Data. Int. J. Environ. Res. Public Health 2015, 12, 1548–1559
por: Burstyn, Igor, et al.
Publicado: (2016)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ufsoqq1dipa4kb38rmoamllvg2